Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, Meyerson M, Gabriel SB, Lander ES, Getz G. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014;505:495–501.
NOTES
Lawrence, Michael SStojanov, PetarMermel, Craig HRobinson, James TGarraway, Levi AGolub, Todd RMeyerson, MatthewGabriel, Stacey BLander, Eric SGetz, GadengR01 CA157304/CA/NCI NIH HHS/T32 GM007753/GM/NIGMS NIH HHS/U54 HG003067/HG/NHGRI NIH HHS/Howard Hughes Medical Institute/Research Support, N.I.H., ExtramuralResearch Support, Non-U.S. Gov'tEnglandNature. 2014 Jan 23;505(7484):495-501. doi: 10.1038/nature12912. Epub 2014 Jan 5.
Abstract
Although a few cancer genes are mutated in a high proportion of tumours of a given type (>20%), most are mutated at intermediate frequencies (2-20%). To explore the feasibility of creating a comprehensive catalogue of cancer genes, we analysed somatic point mutations in exome sequences from 4,742 human cancers and their matched normal-tissue samples across 21 cancer types. We found that large-scale genomic analysis can identify nearly all known cancer genes in these tumour types. Our analysis also identified 33 genes that were not previously known to be significantly mutated in cancer, including genes related to proliferation, apoptosis, genome stability, chromatin regulation, immune evasion, RNA processing and protein homeostasis. Down-sampling analysis indicates that larger sample sizes will reveal many more genes mutated at clinically important frequencies. We estimate that near-saturation may be achieved with 600-5,000 samples per tumour type, depending on background mutation frequency. The results may help to guide the next stage of cancer genomics.
Last updated on 02/17/2021